vs

Side-by-side financial comparison of Alset Inc. (AEI) and FATE THERAPEUTICS INC (FATE). Click either name above to swap in a different company.

FATE THERAPEUTICS INC is the larger business by last-quarter revenue ($1.4M vs $1.3M, roughly 1.0× Alset Inc.). On growth, FATE THERAPEUTICS INC posted the faster year-over-year revenue change (-26.4% vs -85.4%). Alset Inc. produced more free cash flow last quarter ($-6.1M vs $-112.0M). Over the past eight quarters, FATE THERAPEUTICS INC's revenue compounded faster (-15.7% CAGR vs -53.7%).

Alset Global GmbH is an Austrian technology and engineering company based in Graz that specialises in hydrogen-based clean mobility products. Alset Global is known for developing a Hybrid Hydrogen internal combustion engine that can run on either pure petrol, pure hydrogen or a combination of both. This technology offers a sustainable and clean alternative to petrol-based internal combustion engines. The technology has been developed to create an alternative technology to meet new emission ta...

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

AEI vs FATE — Head-to-Head

Bigger by revenue
FATE
FATE
1.0× larger
FATE
$1.4M
$1.3M
AEI
Growing faster (revenue YoY)
FATE
FATE
+59.0% gap
FATE
-26.4%
-85.4%
AEI
More free cash flow
AEI
AEI
$105.9M more FCF
AEI
$-6.1M
$-112.0M
FATE
Faster 2-yr revenue CAGR
FATE
FATE
Annualised
FATE
-15.7%
-53.7%
AEI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AEI
AEI
FATE
FATE
Revenue
$1.3M
$1.4M
Net Profit
Gross Margin
35.2%
Operating Margin
Net Margin
Revenue YoY
-85.4%
-26.4%
Net Profit YoY
-1491.5%
37.9%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AEI
AEI
FATE
FATE
Q4 25
$1.3M
$1.4M
Q3 25
$998.8K
$1.7M
Q2 25
$1.1M
$1.9M
Q1 25
$1.1M
$1.6M
Q4 24
$8.9M
$1.9M
Q3 24
$5.0M
$3.1M
Q2 24
$1.1M
$6.8M
Q1 24
$6.1M
$1.9M
Net Profit
AEI
AEI
FATE
FATE
Q4 25
Q3 25
$1.5M
$-32.3M
Q2 25
$-8.2M
$-34.1M
Q1 25
$-8.3M
$-37.6M
Q4 24
$2.3M
Q3 24
$1.7M
$-47.7M
Q2 24
$-1.2M
$-38.4M
Q1 24
$-6.8M
$-48.0M
Gross Margin
AEI
AEI
FATE
FATE
Q4 25
35.2%
Q3 25
24.3%
Q2 25
23.3%
Q1 25
27.2%
Q4 24
51.4%
Q3 24
40.5%
Q2 24
26.4%
Q1 24
23.5%
Operating Margin
AEI
AEI
FATE
FATE
Q4 25
Q3 25
-258.2%
-1995.1%
Q2 25
-250.7%
-1938.5%
Q1 25
-368.1%
-2534.1%
Q4 24
21.5%
Q3 24
-19.4%
-1703.9%
Q2 24
-249.3%
-665.7%
Q1 24
-37.2%
-2652.9%
Net Margin
AEI
AEI
FATE
FATE
Q4 25
Q3 25
151.4%
-1852.4%
Q2 25
-748.1%
-1786.6%
Q1 25
-780.1%
-2309.5%
Q4 24
26.0%
Q3 24
34.6%
-1551.0%
Q2 24
-109.9%
-567.4%
Q1 24
-111.2%
-2493.7%
EPS (diluted)
AEI
AEI
FATE
FATE
Q4 25
Q3 25
$0.05
$-0.27
Q2 25
$-0.71
$-0.29
Q1 25
$-0.78
$-0.32
Q4 24
$0.24
Q3 24
$0.19
$-0.40
Q2 24
$-0.13
$-0.33
Q1 24
$-0.73
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AEI
AEI
FATE
FATE
Cash + ST InvestmentsLiquidity on hand
$25.2M
$203.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$121.1M
$207.2M
Total Assets
$136.6M
$318.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AEI
AEI
FATE
FATE
Q4 25
$25.2M
$203.7M
Q3 25
$25.5M
$215.4M
Q2 25
$25.6M
$222.8M
Q1 25
$25.2M
$240.4M
Q4 24
$27.2M
$279.1M
Q3 24
$16.7M
$296.9M
Q2 24
$18.9M
$304.9M
Q1 24
$23.7M
$121.3M
Total Debt
AEI
AEI
FATE
FATE
Q4 25
Q3 25
Q2 25
Q1 25
$116.5K
Q4 24
$123.1K
Q3 24
$137.9K
Q2 24
$137.8K
Q1 24
$145.8K
Stockholders' Equity
AEI
AEI
FATE
FATE
Q4 25
$121.1M
$207.2M
Q3 25
$155.7M
$234.1M
Q2 25
$72.8M
$261.4M
Q1 25
$76.4M
$288.4M
Q4 24
$81.3M
$318.7M
Q3 24
$84.2M
$362.3M
Q2 24
$79.4M
$397.0M
Q1 24
$81.7M
$426.1M
Total Assets
AEI
AEI
FATE
FATE
Q4 25
$136.6M
$318.9M
Q3 25
$169.1M
$343.7M
Q2 25
$86.0M
$371.6M
Q1 25
$90.5M
$398.7M
Q4 24
$96.8M
$440.7M
Q3 24
$98.8M
$495.0M
Q2 24
$93.5M
$528.8M
Q1 24
$96.7M
$569.9M
Debt / Equity
AEI
AEI
FATE
FATE
Q4 25
Q3 25
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AEI
AEI
FATE
FATE
Operating Cash FlowLast quarter
$-5.9M
$-106.1M
Free Cash FlowOCF − Capex
$-6.1M
$-112.0M
FCF MarginFCF / Revenue
-467.7%
-8183.9%
Capex IntensityCapex / Revenue
13.4%
434.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-11.8M
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AEI
AEI
FATE
FATE
Q4 25
$-5.9M
$-106.1M
Q3 25
$883.4K
$-24.4M
Q2 25
$-2.6M
$-24.6M
Q1 25
$-3.8M
$-33.8M
Q4 24
$5.2M
$-122.9M
Q3 24
$-2.9M
$-29.4M
Q2 24
$-4.4M
$-32.3M
Q1 24
$-1.5M
$-33.4M
Free Cash Flow
AEI
AEI
FATE
FATE
Q4 25
$-6.1M
$-112.0M
Q3 25
$822.4K
$-26.6M
Q2 25
$-2.7M
$-25.9M
Q1 25
$-3.8M
$-35.0M
Q4 24
$5.1M
$-123.6M
Q3 24
$-2.9M
$-29.9M
Q2 24
$-4.4M
$-32.4M
Q1 24
$-1.5M
$-33.4M
FCF Margin
AEI
AEI
FATE
FATE
Q4 25
-467.7%
-8183.9%
Q3 25
82.3%
-1526.5%
Q2 25
-245.9%
-1360.7%
Q1 25
-357.3%
-2148.9%
Q4 24
56.5%
-6645.4%
Q3 24
-58.2%
-973.1%
Q2 24
-392.3%
-477.8%
Q1 24
-24.8%
-1736.9%
Capex Intensity
AEI
AEI
FATE
FATE
Q4 25
13.4%
434.8%
Q3 25
6.1%
126.5%
Q2 25
7.6%
71.4%
Q1 25
5.7%
73.4%
Q4 24
1.1%
39.2%
Q3 24
0.6%
16.1%
Q2 24
3.0%
0.8%
Q1 24
0.0%
4.5%
Cash Conversion
AEI
AEI
FATE
FATE
Q4 25
Q3 25
0.58×
Q2 25
Q1 25
Q4 24
2.22×
Q3 24
-1.66×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons